Design and evaluation of biodegradable enteric microcapsules of amifostine for oral delivery

International Journal of Pharmaceutics

Volumn 453, Issue 2, 2013, Pages 441-447

  Gula, A ^a,b   Ren, Lei ^a   Zhou, Zhe ^a   Lu, Dandan ^a   Wang, Shengqi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b Qingdao First Sanatorium of Jinan Military Command ^*  (China)

Author keywords

Amifostine; Enteric microcapsule; Eudragit; Oral delivery; Radioprotection

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; EUDRAGIT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; GAMMA IRRADIATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; LOW DRUG DOSE; MALE; METABOLITE; MICROCAPSULE; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION PROTECTION; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; TISSUE DISTRIBUTION;

EID: 84884163854     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.019     Document Type: Article

References (16)

1. Bonner, H.S., Shaw, L.M., 2002. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J. Clin. Pharmacol. 42, 166-174. (Pubitemid 34101349)
2. Brizel, D.M., Wasserman, T.H., Henke, M., Strnad, V., Rudat, V., Monnier, A., Eschwege, F., Zhang, J., Russell, L., Oster, W., 2000. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18, 3339-3345.
3. Capizzi, R.L., 1999. Clinical status and optimal use of amifostine. Oncology-Huntington 13, 47-62.
4. Cassatt, D.R., Fazenbaker, C.A., Bachy, C.M., Hanson, M.S., 2002. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin. Radiat. Oncol. 12, 97-102. (Pubitemid 34246077)
5. Fatome, M., Courteille, F., Laval, J.D., Roman, V., 1987. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration. Int. J. Radiat. Biol. 52, 21-29. (Pubitemid 17104595)
6. Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., Glick, J., 1996. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14, 2101-2112. (Pubitemid 26230113)
7. Koukourakis, M.I., 2002. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 13, 181-209. (Pubitemid 34492701)
8. Koukourakis, M.I., Kyrias, G., Kakolyris, S., Kouroussis, C., Frangiadaki, C., Giatromanolaki, A., Retalis, G., Georgoulias, V., 2000. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J. Clin. Oncol. 18, 2226-2233. (Pubitemid 30350214)
9. Koukourakis, M.I., Panteliadou, M., Abatzoglou, I.M., Sismanidou, K., Sivridis, E., Giatromanolaki, A., 2013. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection. Int. J. Radiat. Oncol. Biol. Phys. 85, e7-e13.
10. Menard, C., Camphausen, K., Muanza, T., Sears-Crouse, N., Smith, S., Ben-Josef, E., Coleman, C.N., 2003. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results. Semin. Oncol. 30, 63-67. (Pubitemid 38120501)
11. Mothersill, C., Kadhim, M.A., O'Reilly, S., Papworth, D., Marsden, S.J., Seymour, C.B., Wright, E.G., 2000. Dose- and time-response relationships for lethal mutations and chromosomal instability induced by ionizing radiation in an immortalized human keratinocyte cell line. Int. J. Radiat. Biol. 76, 799-806. (Pubitemid 30352763)
12. Pamujula, S., Graves, R.A., Freeman, T., Srinivasan, V., Bostanian, L.A., Kishore, V., Mandal, T.K., 2004. Oral delivery of spray dried PLGA/amifostine nanoparticles. J. Pharm. Pharmacol. 56, 1119-1125. (Pubitemid 39207192)
13. Pamujula, S., Kishore, V., Rider, B., Fermin, C.D., Graves, R.A., Agrawal, K.C., Mandal, T.K., 2005. Radioprotection in mice following oral delivery of amifostine nanoparticles. Int. J. Radiat. Biol. 81, 251-257. (Pubitemid 40911075)
14. Pamujula, S., Kishore, V., Rider, B., Agrawal, K.C., Mandal, T.K., 2008. Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles. Int. J. Radiat. Biol. 84, 900-908. (Pubitemid 352766022)
15. Schuchter, L.M., Hensley, M.L., Meropol, N.J., Winer, E.P., 2002. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 20, 2895-2903. (Pubitemid 34651519)
16. Small, W., 2003. Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the radiation therapy oncology group C- 0116 trial. Semin. Oncol. 30, 68-71.